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Tuberculosis is the second most fatal disease in the world which is caused by Mycobacterium 
tuberculosis (MT) [1]. Different therapeutic regimens have been used in the past but drug 
resistance always led low patient compliance. As the bacteria resides inside macrophage 
during the disease phase, so developing a drug delivery system containing nanoparticles which 
can directly target the causative organism inside macrophage can prove to be the modern day 
anti TB therapy [2]. Various routes of drug administration have been explored using 
nanoparticles in the past but pulmonary route proves to be the most promising one [3, 4]. 
During nanoparticle formulation comprised of Hyaluronic acid (HA) or Chitosan, core can serve 
as a reservoir for various drugs for targeting macrophages in TB. Chitosan is mucoadhesive in 
nature and HA has an affinity for the macrophage, so these are the biodegradable polymers 
of choice [5]. Amoxicillin and various other drugs will be compared in terms of efficacy for 
reducing the symptoms of TB. Physicochemical tests including FT-IR, DSC, TGA, XRPD, SEM, 
size analyses and aerodynamic characterization can provide useful data about compatibility 
and stability of the nanoparticular system. Ex Vivo Drug Accumulation Studies on Cultured 
Alveolar Macrophages and stability of the formulation in Broncheo-Alveolar Lavage Fluid can 
be performed prior to the in vivo testing in Guinea pigs. Inhibition of bacilli growth in 
macrophage can reduce the production of pro inflammatory cytokines and chemokines. 
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